Inspira Technologies Oxy B.H.N. Ltd. (NASDAQ:IINN) Short Interest Down 39.1% in February

Inspira Technologies Oxy B.H.N. Ltd. (NASDAQ:IINN) was the recipient of a large drop in short interest in February. As of February 15th, there was short interest totalling 520,300 shares, a drop of 39.1% from the January 31st total of 853,700 shares. Approximately 2.4% of the shares of the stock are sold short. Based on an average daily trading volume, of 1,100,000 shares, the days-to-cover ratio is presently 0.5 days.

Institutional Inflows and Outflows

A hedge fund recently raised its stake in Inspira Technologies Oxy B.H.N. stock. Renaissance Technologies LLC boosted its stake in Inspira Technologies Oxy B.H.N. Ltd. (NASDAQ:IINN) by 142.7% during the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 36,622 shares of the company’s stock after buying an additional 21,532 shares during the quarter. Renaissance Technologies LLC owned approximately 0.29% of Inspira Technologies Oxy B.H.N. worth $37,000 at the end of the most recent reporting period. 12.72% of the stock is owned by institutional investors.

Inspira Technologies Oxy B.H.N. Price Performance

Inspira Technologies Oxy B.H.N. stock traded down $0.03 during midday trading on Tuesday, reaching $0.84. The company had a trading volume of 657,177 shares, compared to its average volume of 1,656,892. Inspira Technologies Oxy B.H.N. has a 12-month low of $0.77 and a 12-month high of $2.45. The firm’s fifty day simple moving average is $0.96 and its 200-day simple moving average is $1.15. The company has a current ratio of 2.23, a quick ratio of 2.13 and a debt-to-equity ratio of 0.09.

About Inspira Technologies Oxy B.H.N.

Inspira Technologies Oxy B.H.N. Ltd., a specialty medical device company, engages in the research, development, manufacture, and marketing of respiratory support technology to provide an alternative to invasive mechanical ventilation for the treatment of acute respiratory failure. Its lead product is the augmented respiration technology system, a respiratory support system comprising minimally invasive, portable dual lumen cannula, which is inserted into the jugular vein and utilizes extra-corporeal direct blood oxygenation to elevate and stabilize declining oxygen saturation levels.